



WHAT IS CLAIMED IS:

1. A compound of the formula:



in which A is a moiety of the formula




where the dotted line represents optional unsaturation,

includes

≡

or the cycloalkenyl moiety



R₁ is hydrogen or alkyl of 1 to 6 carbon atoms;

R₂ is alkyl of 1 to 6 carbon atoms;

R₄ is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanoyl of 2 to 7 carbon atoms;

R₅ and R₆ are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or, when taken together, methylene dioxy;

R₇ is hydrogen or alkyl of 1 to 6 carbon atoms; and

n is one of the integers 0, 1, 2, 3 or 4;

or a pharmaceutically acceptable salt thereof.

B 2. A compound of ~~Claim 2~~ in which in which R₁ is hydrogen or alkyl of 1 to 3 carbon atoms; R₂ is alkyl of 1 to 3 carbon atoms; R₅ is hydrogen, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkyl of 1 to 3 carbon atoms; R₆ is alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, chloro, bromo, trifluoromethyl or alkanoyloxy of 2 to 3 carbon atoms; R₇ is hydrogen or alkyl of 1 to 3 carbon atoms; or a pharmaceutically acceptable salt thereof.

3. A compound of ~~Claim 2~~ in which R₅ and R₆ are in meta or para positions and n is 2.

4. The compound of ~~Claim 2~~ which is 1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

5. The compound of ~~Claim 2~~ which is 1-(α -[(dimethylamino)methyl]benzyl)cyclohexanol or a pharmaceutically acceptable salt thereof.

6. The compound of ~~Claim 2~~ which is 1-(α -[methylamino]-methyl)benzyl)cyclohexanol or a pharmaceutically acceptable salt thereof.

7. The compound of ~~Claim 2~~ which is 1-[1-(4-chlorophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

8. The compound of ~~Claim 2~~ which is 1-[1-(4-methoxyphenyl)-2-(methylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

9. The compound of ~~Claim 1~~ which is 1-[1-(4-bromo-phenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

10. The compound of ~~Claim 1~~ which is 1-[1-(3-bromo-phenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

11. The compound of ~~Claim 1~~ which is 1-[1-(3-chloro-phenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

12. The compound of ~~Claim 1~~ which is 1-[1-(2-chloro-phenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

13. The compound of ~~Claim 1~~ which is 1-[1-(3,4-dichloro-phenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

14. The compound of ~~Claim 1~~ which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexene or a pharmaceutically acceptable salt thereof.

15. The compound of ~~Claim 1~~ which is 1-[2-(dimethylamino)-1-(3-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

16. The compound of ~~Claim 1~~ which is 1-[1-(3,4-dimethoxyphenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

17. The compound of ~~Claim~~^{37/} which is 1-[2-(dimethylamino)-1-(4-trifluoromethylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

18. The compound of ~~Claim~~^{37/} which is 1-[2-(dimethylamino)-1-(3-trifluoromethylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

19. The compound of ~~Claim~~^{37/} which is 1-[2-(dimethylamino)-1-(4-methylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

20. The compound of ~~Claim~~^{37/} which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohex-2-en-1-ol or a pharmaceutically acceptable salt thereof.

21. The compound of ~~Claim~~^{37/} which is 1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

22. The compound of ~~Claim~~^{37/} which is 1-[2-(dimethylamino)-1-(3-hydroxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

23. The compound of ~~Claim~~^{37/} which is 1-[1-(4-amino-phenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

24. The compound of ~~Claim~~^{37/} which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclopentanol or a pharmaceutically acceptable salt thereof.

25. The compound of Claim 27 which is 1-[1-(4-nitrophenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

26. The compound of Claim 27 which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cycloheptanol or a pharmaceutically acceptable salt thereof.

27. The compound of Claim 27 which is 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclooctanol or a pharmaceutically acceptable salt thereof.

28. The compound of Claim 27 which is 1-[2-(dimethylamino)-1-(3-bromo-4-methoxyphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

29. The compound of Claim 27 which is 1-[1-(3,4-dibromo-phenyl)-2-(dimethylamino)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

30. The compound of Claim 27 which is 1-[2-(dimethylamino)-1-(3-methylphenyl)ethyl]cyclohexanol or a pharmaceutically acceptable salt thereof.

31. The compound of Claim 27 which is 1-[1-(4-bromo-phenyl)-2-(dimethylamino)ethyl]cyclobutanol or a pharmaceutically acceptable salt thereof.


32. The compound of Claim 27 which is 1-[2-(dimethylamino)-1-(3-methoxyphenyl)ethyl]cyclopentanol or a pharmaceutically acceptable salt thereof.

END

49


14 *35/*
35. The compound of Claim ~~1~~ which is $\text{H}_2\text{-[1-(dimethylamino)-2-(4-methoxyphenyl)propyl]} \text{cyclohexanol}$ or a pharmaceutically acceptable salt thereof.

34. A compound of the formula



in which the dotted line represents optional unsaturation,
 R_4 is hydrogen or alkyl of 1 to 6 carbon atoms;
 R_5 and R_6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, aralkoxy of 7 to 9 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, alkylmercapto of 1 to 6 carbon atoms, halo or trifluoromethyl;
 R_7 is hydrogen or alkyl of 1 to 6 carbon atoms; and
 n is one of the integers 0, 1, 2, 3 or 4.


35. A compound of the formula




in which the dotted line represents optional unsaturation,

R_1 is hydrogen or alkyl of 1 to 6 carbon atoms;
 R_2 is alkyl of 1 to 6 carbon atoms;
 R_4 is hydrogen or alkyl of 1 to 6 carbon atoms;
 R_5 and R_6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, aralkoxy of 7 to 9 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, alkylmercapto of 1 to 6 carbon atoms, N-protected amino, halo, trifluoromethyl, or when taken together, methylenedioxy;
 R_7 is hydrogen or alkyl of 1 to 6 carbon atoms;
 n is one of the integers 0, 1, 2, 3 or 4.

36. A process for the production of a compound of the formula:




in which A is a moiety of the formula



where the dotted line represents optional unsaturation,


or the cycloalkenyl moiety



R_1 is hydrogen or alkyl of 1 to 6 carbon atoms;
 R_2 is alkyl of 1 to 6 carbon atoms;


R_4 is hydrogen, alkyl of 1 to 6 carbon atoms, formyl, or alkanoyl of 2 to 7 carbon atoms;
 R_5 and R_6 are independently hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, cyano, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, dialkylamino in which each alkyl group is of 1 to 6 carbon atoms, alkanamido of 2 to 7 carbon atoms, halo, trifluoromethyl, or, when taken together, methylene dioxy;
 R_7 is hydrogen or alkyl of 1 to 6 carbon atoms; and
 n is one of the integers 0, 1, 2, 3 or 4;
or a pharmaceutically acceptable salt thereof, which comprises

(a) reducing an amide of the formula



in which R_1 , R_2 , R_7 and n are defined, supra, the dotted line represents optional unsaturation, R_4 is hydrogen or alkyl of 1 to 6 carbon atoms and R_5 and R_6 are, independently, hydrogen, hydroxyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, aralkoxy of 7 to 9 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, alkylmercapto of 1 to 6 carbon atoms, N-protected amino, halo, trifluoromethyl, or when taken together, methylenedioxy, with the proviso that said reduction is selectively performed with aluminum hydride when the dotted lines represent ring unsaturation;


or (b) reducing a nitrile of the formula



in which R_4 , R_5 , R_6 , R_7 , n and the dotted lines are defined under (a), supra, with the exception that R_5 and R_6 are not methylene-dioxy, to produce an amine, followed by N-mono- or -di-alkylation and optionally

- (1) acylating the product with an active derivative of formic acid or an alcanoic acid containing from 2 to 7 carbon atoms to introduce the R_4 group or an R_1 and/or R_2 acyl group which is subsequently reduced to afford an R_1 and/or R_2 alkyl group;
- (2) deprotecting said N-protected amino substituent to obtain the free amine, mono- or di-alkylating or acylating the amine or diazotizing the amino group and displacing the diazolate salt with a nitrite or a nitrile;
- (3) displacing a halo substituent with a nitrile;
- (4) dehydrating to introduce unsaturation into the cycloalkanyl ring


or (c) subjecting an aldehyde of the formula



in which R_4 , R_5 , R_6 , R_7 , n and the dotted lines are defined under (a), supra, (1) to amination with hydroxylamine, ammonia, a pri-

mary alkylamine or a secondary alkylamine followed by reduction or (2) to reductive amination with an amine of the formula HNR_1R_2 and a reducing agent

or (d) subjecting a compound of the formula



in which R_4 , R_5 , R_6 , R_7 , n and the dotted lines are defined under (a), supra, and Z is a leaving group to reaction with ammonia or HNR_1R_2 where in R_1 and R_2 are defined in (a), supra, followed by alkylation of the product obtained in the reaction with ammonia.

Add 7
B'